Skip to main content

Table 2 Effects of coenzyme Q10 supplementation on study outcomes

From: Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial

 

Q10 (n = 26)

Placebo (n = 26)

P-value (Between-group)

Baseline

End

P-value (within group)

Baseline

End

P-value (within-group)

MDA (nmol/ml)

26.50 ± 3.98

26.92 ± 2.70

0.573

31.93 ± 7.02

31.03 ± 6.49

0.178

0.692

SOD activity (U SOD activity/ml)

14.33 ± 3.03

13.38 ± 2.87

0.197

13.40 ± 2.54

13.48 ± 4.66

0.715

0.633

TAC (nmol of trolox equivalent/ml)

32.25 ± 4.12

34.16 ± 10

0.412

32.45 ± 4.33

34.54 ± 7.90

0.247

0.865

CRP (mg/l)

128.21 ± 69.61

78.60 ± 63.72

0.002

133.15 ± 82.50

90.49 ± 68.57

0.01

0.550

ESR (mm)

57.27 ± 33.00

69.62 ± 22.54

0.098

50.27 ± 27.55

61.96 ± 22.86

0.059

0.306

Albumin (mg/dl)

2.93 ± 0.32

3.26 ± 0.48

0.008

2.86 ± 0.43

2.97 ± 0.42

0.180

0.031

PT

14.09 ± 1.30

14.10 ± 1.79

0.968

13.53 ± 0.92

14.16 ± 1.56

0.085

0.677

PTT

37.12 ± 17.42

36.69 ± 5.06

0.551

35.12 ± 5.05

39.92 ± 10.10

0.012

0.144

INR

1.14 ± 0.17

1.14 ± 0.24

0.99

1.07 ± 0.12

1.14 ± 0.17

0.102

0.795

BUN (mg/dl)

13.55 ± 2.74

13.44 ± 3.56

0.847

15.83 ± 6.18

15.20 ± 7.72

0.697

0.655

Cr (mg/dl)

0.87 ± 0.13

0.87 ± 0.14

0.879

0.91 ± 0.14

0.91 ± 0.14

0.99

0.575

FBG (mg/dl)

120.92 ± 66.17

93.12 ± 17.30

0.046

99.12 ± 27.45

94.00 ± 18.77

0.383

0.743

RBC (106/µL)

3.90 ± 0.80

3.59 ± 0.55

0.020

3.75 ± 0.79

3.43 ± 0.40

0.021

0.346

Hemoglobin (g/dl)

11.12 ± 2.48

10.11 ± 1.47

0.021

11.17 ± 2.69

9.91 ± 1.28

0.010

0.524

Hematocrit (%)

33.55 ± 6.16

30.72 ± 3.74

0.016

33.72 ± 7.23

30.30 ± 3.43

0.009

0.598

MCV (fL)

85.94 ± 6.99

86.10 ± 5.30

0.754

88.28 ± 3.76

88.39 ± 3.68

0.789

0.304

MCH (pg)

28.39 ± 2.83

28.27 ± 2.02

0.618

29.10 ± 1.52

28.92 ± 1.49

0.439

0.514

MCHC (g/dl)

33.03 ± 1.94

32.56 ± 2.04

0.399

32.97 ± 1.36

32.72 ± 1.63

0.431

0.732

WBC (µL)

9519.23 ± 3604.78

9000 ± 2915.61

0.531

12161.54 ± 4883.94

10,396.15 ± 7255.59

0.275

0.605

Lymphocyte (%)

17.37 ± 7.87

19.62 ± 7.87

0.302

15.94 ± 7.19

16.75 ± 6.92

0.653

0.197

Neutrophil (%)

74.02 ± 8.69

72.75 ± 8.14

0.561

77.75 ± 10.53

76.75 ± 9.58

0.716

0.154

Platelet (103/µL)

270.08 ± 138.23

409.19 ± 144.05

0.000

233.96 ± 95.96

376.08 ± 171.44

0.000

0.678

Mean temperature (°C)

37.44 ± 0.28

37.39 ± 0.34

0.488

37.36 ± 0.31

37.49 ± 0.41

0.118

0.172

Mean systolic BP (mmHg)

129.54 ± 10.93

124.77 ± 9.02

0.029

128.82 ± 12.57

125.43 ± 9.35

0.158

0.693

Mean diastolic BP (mmHg)

68.76 ± 8

70.55 ± 6.60

0.309

70.54 ± 8.06

68.44 ± 6.39

0.216

0.148

Mean O2 Sat (%)

95.83 ± 1.41

96.05 ± 1.26

0.567

95.79 ± 1.11

96.22 ± 1.17

0.165

0.610

ICU duration (days)

18.83 ± 10.72

 

23.60 ± 10.03

 

0.122a

28-day mortality (N)

2 (7.7%)

 

3 (11.5%)

 

0.99b

  1. Data are shown as mean ± standard deviation or n (%)
  2. Between-group and within-group differences were tested with ANCOVA and paired t-test respectively
  3. Abbreviations: MDA malondialdehyde, SOD superoxide dismutase, TAC total antioxidant capacity, CRP C-reactive protein, ESR erythrocyte sedimentation rate, PT prothrombin time, PTT partial thromboplastin time, INR international normalized ratio, BUN blood urea nitrogen, Cr creatinine, FBG fasting blood glucose, RBC red blood cell, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentration, WBC white blood cell, BP blood pressure, O2 Sat oxygen saturation, ICU intensive care unit
  4. aComparison of Q10 and placebo group based on independent t-tests
  5. bComparison of Q10 and placebo group based on Fisher’s exact test
Back to article page

Trials

ISSN: 1745-6215